

Electronic Supplementary Information










A Modular Total Synthesis of Trigonoliimine C











B Narendraprasad Reddy and Chepuri V. Ramana*

CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road,
Pune – 411 008 (India).

Email: vr.cheipuri@ncl.res.in

Table of content	ESI 2
General remarks	ESI 4
General procedure A: Addition of 3-methyl indole to isatogen	ESI 4
General procedure B: N-hydroxy indoxyl reduction.....	ESI 5
General Procedure C: N-Phth deprotection and cyclization.....	ESI 6
Synthesis of (\pm)-Trigonoliimine C	ESI 17
Comparison of ^{13}C NMR Spectra for Synthetic Trigonoliimine C and Natural Trigonoliimine C	ESI 18

S. No	Compound	Data	Page No
1		Characterization data	ESI 5
		¹ H NMR Spectrum	ESI 19
		¹ H NMR Spectrum(Acetone-D ₆)	ESI 20
		¹³ C NMR Spectrum	ESI 21
		DEPT Spectrum	ESI 22
2		Characterization data	ESI 5
		¹ H NMR Spectrum	ESI 25
		¹³ C NMR Spectrum	ESI 26
		DEPT Spectrum	ESI 27
		Mass Spectrum (ESI + HRMS)	ESI 28 & ESI 29
3		Characterization data	ESI 6
		¹ H NMR Spectrum	ESI 30
		¹³ C NMR Spectrum	ESI 31
		DEPT Spectrum	ESI 32
		Mass Spectrum (ESI + HRMS)	ESI 33 & ESI 34
4		Characterization data	ESI 7
		¹ H NMR Spectrum	ESI 35
		¹³ C NMR Spectrum	ESI 36
		DEPT Spectrum	ESI 37
		Mass Spectrum (ESI + HRMS)	ESI 38 & ESI 39
5		Characterization data	ESI 7
		¹ H NMR Spectrum	ESI 40
		¹³ C NMR Spectrum	ESI 41
		DEPT Spectrum	ESI 42
		Mass Spectrum (ESI + HRMS)	ESI 43 & ESI 44
6		Characterization data	ESI 8
		¹ H NMR Spectrum	ESI 45
		¹³ C NMR Spectrum	ESI 46
		DEPT Spectrum	ESI 47
		Mass Spectrum (ESI + HRMS)	ESI 48 & ESI 49
7		Characterization data	ESI 9
		¹ H NMR Spectrum	ESI 50
		¹³ C NMR Spectrum	ESI 51
		DEPT Spectrum	ESI 52
		Mass Spectrum (ESI + HRMS)	ESI 53 & ESI 54
8		Characterization data	ESI 9
		¹ H NMR Spectrum	ESI 55
		¹³ C NMR Spectrum	ESI 56
		DEPT Spectrum	ESI 57
		Mass Spectrum (ESI + HRMS)	ESI 58 & ESI 59
9		Characterization data	ESI 10
		¹ H NMR Spectrum	ESI 60
		¹³ C NMR Spectrum	ESI 61
		DEPT Spectrum	ESI 62
		Mass Spectrum (ESI + HRMS)	ESI 63 & ESI 64


S. No	Compound	Data	Page No
10		Characterization data	ESI 11
		¹ H NMR Spectrum	ESI 65
		¹³ C NMR Spectrum	ESI 66
		DEPT Spectrum	ESI 67
		Mass Spectrum (ESI + HRMS)	ESI 68 & ESI 69
11		Characterization data	ESI 11
		¹ H NMR Spectrum	ESI 70
		¹³ C NMR Spectrum	ESI 71
		DEPT Spectrum	ESI 72
		Mass Spectrum (ESI + HRMS)	ESI 73 & ESI 74
12		Characterization data	ESI 12
		¹ H NMR Spectrum	ESI 75
		¹³ C NMR Spectrum	ESI 76
		DEPT Spectrum	ESI 77
		Mass Spectrum (ESI + HRMS)	ESI 78 & ESI 79
13		Characterization data	ESI 13
		¹ H NMR Spectrum	ESI 80
		¹³ C NMR Spectrum	ESI 81
		DEPT Spectrum	ESI 82
		Mass Spectrum (ESI + HRMS)	ESI 83 & ESI 84
14		Characterization data	ESI 13
		¹ H NMR Spectrum	ESI 85
		¹³ C NMR Spectrum	ESI 86
		DEPT Spectrum	ESI 87
		Mass Spectrum (ESI + HRMS)	ESI 88 & ESI 89
15		Characterization data	ESI 14
		¹ H NMR Spectrum	ESI 90
		¹³ C NMR Spectrum	ESI 91
		DEPT Spectrum	ESI 92
		Mass Spectrum (ESI + HRMS)	ESI 93 & ESI 94
16		Characterization data	ESI 15
		¹ H NMR Spectrum	ESI 95
		¹³ C NMR Spectrum	ESI 96
		DEPT Spectrum	ESI 97
		Mass Spectrum (ESI + HRMS)	ESI 98 & ESI 99
17		Characterization data	ESI 15
		¹ H NMR Spectrum	ESI 100
		¹³ C NMR Spectrum	ESI 101
		DEPT Spectrum	ESI 102
		Mass Spectrum (HRMS)	ESI 103
18		Characterization data	ESI 16
		¹ H NMR Spectrum	ESI 104
		¹³ C NMR Spectrum	ESI 105
		DEPT Spectrum	ESI 106
		Mass Spectrum (ESI + HRMS)	ESI 107 & ESI 108
19		Characterization data	ESI 17
		¹ H NMR Spectrum	ESI 109
		¹³ C NMR Spectrum	ESI 110
		DEPT Spectrum	ESI 111
		Mass Spectrum (ESI + HRMS)	ESI 112 & ESI 113

General Remarks

Reactions were carried out in anhydrous solvents under an atmosphere of argon in oven-dried glassware. Commercial reagents and solvents were used without purification. Column Chromatography was carried out by using spectrochem silica gel (60–120, 100–200, 230–400 mesh). ^1H and ^{13}C NMR spectroscopy measurements were carried out on Bruker AV 200 MHz AV 400, AV 500 MHz and JEOL 400 spectrometers, and TMS was used as an internal standard. ^1H and ^{13}C NMR chemical shifts are reported in ppm downfield from Chloroform-d ($\delta = 7.25$) or TMS and coupling constants (J) are reported in Hertz (Hz). The following abbreviations are used to designate signal multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dt = doublet of triplet, td = triplet of doublet, bs = broad. The multiplicity of ^{13}C NMR signals was assigned with the help of DEPT spectra and the abbreviations used: s = singlet, d = doublet, t = triplet, q = quartet, represent C (quaternary), CH, CH_2 and CH_3 respectively. Mass spectroscopy was carried out on a API QStar Pulsar (Hybrid Quadrupole-TOF LC/MS/MS) spectrometer or UPLC coupled Mass Spectrometer (Waters) and HRMS mass spectra were recorded on a Thermo Scientific Q-Exactive, Accela 1250 pump.


General procedure A: Addition of 3-methyl indole to isatogen: To a solution of isatogen **7a** (60 mg, 0.24 mmol) and 3-methyl indole (38 mg, 0.29 mmol) in CH_2Cl_2 (2 mL) was added, $\text{Au}[\text{PPh}_3]\text{Cl}$ (12 mg, 0.6 mmol, 10 mol%), AgSbF_6 (20 mg, 0.6 mmol, 25 mol%) at 0 °C. The reaction mixture was stirred for overnight at room temperature. After completion of the reaction as indicated by TLC, the volatiles are removed under reduced pressure and the resulting crude was purified by column chromatography to afford compound **8a** (69 mg, 75%) as a brown red liquid.

Spectral data of compound 8a: $R_f = 0.3$ (10% ethyl acetate/pet. ether); IR (CHCl_3) ν : 3392, 3255, 2953, 2927, 1670, 1620, 1579, 1458, 1290, 1229, 1149, 1099, 823, 741 cm^{-1} ; **$^1\text{H NMR}$ (Acetone- D_6 , 200 MHz):** δ 0.84 (bs, 3H), 1.31 (bs, 6H), 2.18 (s, 3H), 2.46–2.50 (m, 2H), 3.96 (s, 3H), 6.57 (d, $J = 8.5, 1.5$ Hz, 1H), 6.67 (d, $J = 1.6$ Hz, 1H), 7.05 (m, 2H), 7.33 (d, $J = 7.3$ Hz, 1H), 7.41 (d, $J = 9.1$ Hz, 1H), 7.50 (d, $J = 8.4$ Hz, 1H), 8.98 (s, 1H), 9.98 (bs, 1H); **$^{13}\text{C NMR}$ (CD₃OD, Jeol, 100 MHz):** δ 9.7 (q), 14.4 (q), 23.6 (t), 24.9 (t), 33.3 (t), 34.9 (t), 56.6 (q), 78.5 (s), 95.4 (d), 109.3 (s), 112.2 (d), 112.0 (d), 115.2 (s), 119.1 (d), 119.7 (d), 122.4 (d), 126.1 (d), 130.9 (s), 132.5 (s), 136.9 (s), 166.9 (s), 170.2 (s), 199.2 (s) ppm. ESI-MS (m/z): 401.08 (100%, [M+Na]⁺), 417.18 (5%, [M+K]⁺), HRMS (ESI+): calcd. for C₂₃H₂₇O₃N₂, [M+H]⁺: 379.2016, found 379.2014.



General procedure B: N-hydroxy indoxy reduction: A solution of indoxyl **8a** (60 mg, 0.16 mmol) and hydrazine monohydrate (79 mg, 1.6 mmol) in MeOH (6 ml) was heated to reflux for 2 h. After completion of the reaction, the volatiles are removed under reduced pressure and the crude purified by column chromatography to afford compound **9** (51 mg, 89%) as a brown liquid.


Spectral data of compound 9: $R_f = 0.3$ (10% ethyl acetate/pet. ether); IR (CHCl_3) ν : 3368, 3056, 1738, 1649, 1371, 1252, 1116, 882, 723 cm^{-1} ; **$^1\text{H NMR}$ (CDCl₃, 200 MHz):** δ 0.81 (t, $J = 6.3$ Hz, 3H), 1.23 (bs, 6H), 1.19–2.13 (m, 2H), 2.45 (s, 3H), 3.86 (s, 3H), 5.28 (s, 1H), 6.37 (d, $J = 2.0$ Hz, 1H), 6.67 (dd, $J = 8.6, 2.0$ Hz, 1H), 7.06 (td, $J = 7.1, 1.3$ Hz, 1H), 7.14 (td, $J = 7.1, 1.3$ Hz, 1H), 7.28 (dd, $J = 7.2$ Hz, 1H), 7.48 (d, $J = 7.1$ Hz, 1H), 7.53 (d, $J = 8.6$ Hz, 1H), 9.02 (s, 1H); **$^{13}\text{C NMR}$ (CD₃OD, 50 MHz):** 9.7 (q), 14.0 (q), 22.4 (t), 23.5 (t), 31.8 (t), 39.7 (t), 55.6 (q), 70.2 (s), 94.7 (d), 107.4 (s),



109.5 (d), 110.8 (d), 113.5 (s), 118.1 (d), 119.0 (d), 121.8 (d), 126.6 (d), 129.5 (s), 130.9 (s), 134.7 (s), 162.8 (s), 168.2 (s), 200.0 (s) ppm. ESI-MS (*m/z*): 385.01 (100%, [M+Na]⁺), HRMS (ESI⁺): calcd. for C₂₃H₂₇O₂N₂, [M+H]⁺: 363.2067, found 363.2056.

2-(2-(1-Hydroxy-6-methoxy-3-oxo-2-pentylindolin-2-yl)-1H-indol-3-yl)ethyl)isoindoline-1,3-dione


(10a): The addition of tryptamine **4** (183 mg, 0.63 mmol) to isatogen **7a** (130 mg, 0.52 mmol), was carried out following the general procedure A to obtain indoxylo derivative **10a** (194 mg, 68%) as a brown red liquid; *R*_f = 0.3 (20% ethyl acetate/pet. ether); IR (CHCl₃) *v*: 3262, 3045, 2882, 1765, 1648, 1329, 1268, 1123, 843, 768 cm⁻¹; **¹H NMR (CDCl₃, 500 MHz):** δ 0.78 (t, *J* = 6.4 Hz, 3H), 1.18 (bs, 4H), 1.24–1.32 (m, 2H), 2.24 (dt, *J* = 12.2, 4.3, 3.7 Hz, 1H), 2.36 (dt, *J* = 12.2, 3.7, 2.7 Hz, 1H), 3.27 (t, *J* = 9.2 Hz, 2H), 3.86–3.92 (m, 1H), 3.96 (s, 3H), 3.98–4.05 (m, 1H), 6.63 (dd, *J* = 8.5, 1.2 Hz, 1H), 6.89 (d, *J* = 1.2 Hz, 1H), 7.10 (t, *J* = 7.6 Hz, 1H), 7.16 (t, *J* = 7.3 Hz, 1H), 7.35 (d, *J* = 7.9 Hz, 1H), 7.58 (d, *J* = 8.5 Hz, 1H), 7.64 (d, *J* = 7.6 Hz, 1H), 7.77 (dd, *J* = 5.2, 2.1 Hz, 2H), 7.90 (dd, *J* = 5.2, 2.1 Hz, 2H), 8.97 (s, 1H), 9.47 (bs, 1H); **¹³C NMR (CDCl₃, 125 MHz):** 14.0 (q), 22.2 (t), 23.7 (t), 24.2 (t), 31.8 (t), 38.5 (t), 39.0 (t), 55.9 (q), 76.2 (s), 96.9 (d), 107.8 (s), 111.1 (d), 112.5 (d), 114.7 (s), 117.9 (d), 119.5 (d), 122.0 (d), 123.6 (d, 2C), 125.2 (d), 128.3 (s), 132.0 (s), 133.4 (s), 134.3 (d, 2C), 135.1 (s), 166.7 (s), 168.3 (s), 169.3 (s), 198.2 (s) ppm; ESI-MS (*m/z*): 560.17 (100%, [M+Na]⁺), HRMS (ESI⁺): calcd. for C₃₂H₃₂O₅N₃, [M+H]⁺: 538.2336, found 538.2336.



General Procedure C: N-Phth deprotection and cyclization: A solution of indoxylo **10a** (110 mg, 0.20 mmol) and hydrazine monohydrate (102 mg, 2.1 mmol) in methanol (5 ml) was heated to reflux for 2 h and then the reaction mixture was concentrated. The resulting crude mixture was dissolved in THF (7 mL) and transferred to a flame-dried flask. After the flask was degassed with purging argon gas and Ti(O*i*-Pr)₄ (116 mg, 0.12 ml, 0.41 mmol) was added drop wise at


room temperature. The reaction mixture was stirred at 75 °C for 2 h. The reaction mixture was concentrated under reduced pressure and the resulting residue was subjected for purification by flash chromatography on neutral silica gel (treated with triethyl amine) to afford the compound **11a** (38 mg, 48%) as a pale yellow liquid.

Spectra data of compound 11a: IR (CHCl₃) ν : 3052, 2929, 2850, 1754, 1566, 1349, 1243, 1182, 1017, 884, 763 cm⁻¹; **¹H NMR(500MHz, CDCl₃):** δ 0.82 (t, J = 6.7 Hz, 3H), 1.24 (bs, 4H), 1.30–1.46 (m, 2H), 2.12 (dt, J = 12.5, 2.7 Hz, 1H), 2.53 (dt, J = 13.1, 4.6 Hz, 1H), 3.06 (dt, J = 16.5, 3.7 Hz, 1H), 3.12 (td, J = 16.8, 3.0 Hz, 1H), 3.76 (s, 3H), 4.23 (td, J = 11.9, 3.7 Hz, 1H), 4.43 (dt, J = 12.8, 3.7, 2.4 Hz, 1H), 6.30 (bs, 1H), 6.42 (d, J = 7.6 Hz, 1H), 7.07 (t, J = 7.3 Hz, 1H), 7.14 (t, J = 7.6 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.52 (d, J = 8.5 Hz, 1H), 8.27 (bs, 1H); **¹³C NMR(125MHz, CDCl₃):** 14.0 (q), 22.4 (t), 23.3 (t), 24.0 (t), 31.8 (t), 40.9 (t), 47.0 (t), 55.4 (q), 68.4 (s), 96.6 (d), 108.3 (d), 110.0 (s), 110.7 (d), 118.1 (d), 119.4 (d), 122.0 (d), 124.2 (d), 129.3 (s), 132.5 (s), 132.6 (s), 135.1 (s), 157.0 (s), 164.7 (s), 172.5 (s) ppm. ESI-MS (*m/z*): 374.15 (60%, [M+H]⁺), HRMS (ESI+): calcd. for C₂₄H₂₈N₃O, [M+H]⁺: 374.2227, found 374.2225.




2-(2-(1-Hydroxy-3-oxo-2-pentylindolin-2-yl)-1H-indol-3-yl)ethylisoindoline-1,3-dione (10b):

The addition of *N*-phthalimido tryptamine **4** (290 mg, 1.0 mmol) to isatogen **7b** (180 mg, 0.83 mmol) has been carried out according to the general procedure A to obtain the N-OH indoxyl derivative **10b** (268 mg, 63%) as a pale yellow solid. R_f = 0.2 (10% ethyl acetate/pet. ether); M.P = 179 °C; IR (CHCl₃) ν : 3368, 2929, 1707, 1605, 1494, 1452, 1397,



1290, 1289, 1102, 1024, 745, 718 cm^{-1} ; **$^1\text{H NMR}$ (CDCl_3 , 200 MHz):** δ 0.77 (t, $J = 3.5$ Hz, 2H), 1.17–1.29 (m, 6H), 2.26–2.28 (m, 2H), 3.29 (t, $J = 8.7$ Hz, 3H), 3.88–4.07 (m, 2H), 7.06–7.21 (m, 3H), 7.33 (d, $J = 7.7$ Hz, 1H), 7.54 (d, $J = 7.9$ Hz, 1H), 7.65–7.68 (app d, $J = 6.7$ Hz, 3H), 7.70 (dd, $J = 5.2, 3.0$ Hz, 2H), 7.91 (dd, $J = 5.0, 3.3$ Hz 2H), 9.06 (s, 1H), 9.41 (s, 1H); **$^{13}\text{C NMR}$ (CDCl_3 , 50 MHz):** δ 13.9 (q), 22.1 (t), 23.7 (t), 24.3 (t), 31.8 (t), 38.5 (t), 39.0 (t), 76.6 (s), 108.1 (s), 111.0 (d), 115.0 (d), 118.0 (d), 119.5 (d), 122.1 (d), 122.7 (d), 123.5 (d, 2C), 125.6 (d), 128.3 (s), 131.9 (s, 2C), 132.9 (s), 134.3 (d, 2C), 135.1 (s), 135.9 (s), 137.8 (d), 164.2 (s), 169.2 (s, 2C), 200.9 (s) ppm. ESI-MS (m/z): 530.24 (100%, $[\text{M}+\text{Na}]^+$), 546.17 (25%, $[\text{M}+\text{K}]^+$), HRMS (ESI $^+$): calcd. for $\text{C}_{31}\text{H}_{30}\text{O}_4\text{N}_3$, $[\text{M}+\text{H}]^+$: 508.2231, found 508.2229.


12b-Pentyl-7,12,12b,13-tetrahydro-6H-azepino[3,2-b:4,5-b']diindole (11b): According to the general procedure C, the treatment of indoxyl **10b** (140 mg, 0.28 mmol) with hydrazine monohydrate (140 mg, 2.8 mmol) followed by $\text{Ti}(\text{O}-\text{i-Pr})_4$ (160 mg, 0.55 mmol) gave the **11b** (48 mg, 51%) as a yellow liquid; $R_f = 0.3$ (10%/0.2% MeOH/Et₃N/CH₂Cl₂); $R_f = 0.3$ (70% ethyl acetate/pet ether); IR (CHCl_3) ν : 3273, 2955, 2925, 2854, 1739, 1615, 1462, 1377, 1294, 1211, 1165, 1024, 824, 743 cm^{-1} ; **$^1\text{H NMR}$ (400MHz, CDCl_3):** δ 0.82 (t, $J = 6.8$ Hz, 3H), 1.24 (m, 6H), 1.40 (m, 2H), 2.15 (qd, $J = 4.5$ Hz, 1H), 2.55 (qd, $J = 5.0, 4.8$ Hz, 1H), 3.09 (td, $J = 13.1, 3.8$ Hz, 1H), 3.15 (dt, $J = 13.1, 3.8$ Hz, 1H), 4.23 (dt, $J = 11.8, 3.5$ Hz, 1H), 4.43 (td, $J = 12.5, 4.0, 3.5$ Hz, 1H), 6.79 (d, $J = 8.0$ Hz, 1H), 6.84 (td, $J = 7.5, 0.5$ Hz, 1H), 7.08 (td, $J = 6.8, 1.0$ Hz, 1H), 7.14 (td, $J = 7.0, 1.0$ Hz, 1H), 7.25 (td, $J = 1.2$ Hz, 1H), 7.31 (d, $J = 8.0$ Hz, 1H), 7.48 (d, $J = 7.8$ Hz, 1H), 7.66 (d, $J = 7.5$ Hz 1H), 8.46 (s, 1H); **$^{13}\text{C NMR}$ (100 MHz, CDCl_3):** 13.1 (q), 22.4 (t), 23.1 (t), 24.0 (t), 31.8 (t), 40.7 (t), 47.2 (t), 67.8 (s), 109.9 (s), 110.7 (d), 112.2 (d), 118.1 (d), 119.4 (d), 120.6 (d), 122.0 (d), 123.0



(d), 125.9 (s), 129.2 (s), 132.4 (s), 133.3 (d), 135.1 (s), 155.1 (s), 173.7 (s) ppm. ESI-MS (*m/z*): 344.16 (60%, [M+H]⁺), HRMS (ESI+): calcd. for C₂₃H₂₆N₃, [M+H]⁺: 344.2121, found 344.2120.

2-(3'-(2-(1,3-Dioxoisoindolin-2-yl)ethyl)-6-methyl-3-oxo-2,2'-biindolin-2-yl)ethyl acetate

(10c): The addition of tryptamine **4** (295 mg, 1.02 mmol) to isatogen **7c** (210 mg, 0.85 mmol) was carried out following the general procedure A to obtain indoxyl derivative **10c** (324 mg, 71%) as a yellow solid; *R*_f = 0.3 (30% ethyl acetate/pet. ether); M.P = 118–120



°C; IR (CHCl₃) *v*: 3399, 3225, 2952, 1701, 1628, 1316, 1215, 1108, 821, 745 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz):


(CDCl₃, 500 MHz): δ 1.88 (s, 3H), 2.51 (s, 3H), 2.69 (bs, 2H), 3.29 (app t, 2H), 3.90 (m, 1H), 4.04–4.10 (m, 1H), 4.17 (m, 2H), 6.96 (d, *J* = 7.3 Hz, 1H), 7.12 (t, *J* = 6.4 Hz, 1H), 7.19 (t, *J* = 6.7 Hz, 1H), 7.35 (s, 1H), 7.39 (d, *J* = 7.3 Hz, 1H), 7.59 (d, *J* = 7.3 Hz, 1H), 7.66 (d, *J* = 7.3 Hz, 1H), 7.77 (bs, 2H), 7.92 (bs, 2H), 9.16 (s, 1H), 9.55 (s, 1H); ¹³C NMR (CDCl₃, 125 MHz):

20.6 (q), 22.5 (q), 23.5 (t), 36.6 (t), 38.8 (t), 60.5 (t), 74.8 (s), 96.0 (d), 108.6 (s), 111.1 (d), 115.1 (d), 117.7 (d), 118.8 (s), 119.5 (d), 122.2 (d), 123.4 (d, 2C), 124.8 (d), 128.2 (s), 131.7 (s), 131.8 (s, 2C), 134.2 (d, 2C), 135.2 (s), 149.8 (s), 163.9 (s), 169.1 (s, 2C), 170.6 (s), 198.6 (s) ppm. ESI-MS (*m/z*): 560.17 (100%, [M+Na]⁺), 576.15 (50%, [M+K]⁺), HRMS (ESI+): calcd. for C₃₁H₂₇O₆N₃, [M+Na]⁺: 560.1792, found 560.1791.

2-(2-Methyl-6,7,12,13-tetrahydro-12bH-azepino[3,2-b:4,5-b']diindol-12b-yl)ethan-1-ol

(11c): According to the general procedure C, the treatment of indoxyl

10c (135 mg, 0.25 mmol) with hydrazine monohydrate (125 mg, 2.51 mmol) followed by Ti(O*i*-Pr)₄ (142 mg, 0.5 mmol) gave the **11c** (36 mg, 43%) as a yellow liquid; *R*_f = 0.2 (10%/0.2%




MeOH/Et₃N/CH₂Cl₂); IR (CHCl₃) ν : 3276, 2950, 2729, 1734, 1522, 1360, 1232, 1192, 1021, 893, 723 cm⁻¹; **¹H NMR [500MHz, CD₃OD : CDCl₃ (3:1)]**: δ 2.29 (s, 3H), 2.48 (m, 2H), 3.03 (td, J = 16.5, 3.1 Hz, 1H), 3.16 (app dt, J = 12.5, Hz, 1H), 3.69 (t, J = 5.8 Hz, 2H), 4.02 (d, J = 12.5, Hz, 1H), 4.35 (t, J = 12.5 Hz, 1H), 6.61 (d, J = 7.9 Hz, 1H), 6.63 (bs, 1H), 7.01 (t, J = 7.6 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.9 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H); **¹³C NMR [125MHz, CD₃OD:CDCl₃ (3:1)]**: 22.4 (q), 24.3 (t), 42.0 (t), 47.3 (t), 59.1 (t), 68.7 (s), 110.6 (d), 111.5 (d), 112.8 (d), 118.5 (d), 119.7 (s), 120.7 (s), 121.8 (d), 122.7 (d), 123.9 (d), 129.1 (s), 130.5 (s), 136.3 (s), 147.1 (s), 157.6 (s), 177.4 (s) ppm. ESI-MS (*m/z*): 332.10 (100%, [M+H]⁺), HRMS (ESI+): calcd. for C₂₁H₂₂N₃O, [M+H]⁺: 332.1757, found 332.1757.

3-(2-(3-(2-(1,3-Dioxoisooindolin-2-yl)ethyl)-1H-indol-2-yl)-1-hydroxy-6-methyl-3-oxoindolin-2-yl)propyl acetate (10d):

The addition of tryptamine **4** (146 mg,

0.51 mmol) to isatogen **7d** (110 mg, 0.42 mmol), was carried out following the general procedure A to obtain indoxyl derivative **10d** (142 mg, 61%) as a yellow solid; R_f = 0.3 (30% ethyl acetate/pet. ether); M.P=130–133 °C; IR (CHCl₃) ν : 3392, 3245, 2968, 1721,




1638, 1331, 1256, 1123, 843, 768 cm⁻¹; **¹H NMR (CDCl₃, 200 MHz)**: δ 1.66–1.78 (m, 2H), 2.00 (s, 3H), 2.39 (m, 2H), 2.51 (s, 3H), 3.28–3.35 (m, 2H), 3.98–4.08 (m, 4H), 6.96 (d, J = 8.8 Hz, 1H), 7.17 (bs, 2H), 7.35 (bs, 2H), 7.59 (d, J = 7.7 Hz, 1H), 7.69 (d, J = 6.7 Hz, 1H), 7.79 (bs, 2H), 7.93 (bs, 2H), 9.11 (s, 1H), 9.46 (bs, 1H); **¹³C NMR (CDCl₃:CD₃OD, 100 MHz)**: 20.2 (q), 22.0 (q), 23.5 (t), 23.6 (t), 32.3 (t), 38.3 (t), 64.0 (t), 76.3 (s), 108.3 (s), 110.6 (d), 113.3 (d), 117.7 (d), 118.1 (s), 118.8 (d), 121.4 (d), 122.8 (d, 2C), 123.1 (d), 123.6 (d), 128.4 (s), 131.5 (s), 133.8 (d, 2C), 133.9 (s), 135.1 (s), 150.1 (s), 163.7 (s), 169.1 (s, 2C), 172.0 (s), 198.8 (s); ESI-

MS (*m/z*): 573.97 (100%, [M+Na]⁺), HRMS (ESI+): calcd. for C₃₂H₂₉O₆N₃, [M+Na]⁺: 574.1949, found 574.1943.


3-(2-Methyl-6,7,12,13-tetrahydro-12bH-azepino[3,2-b:4,5-b']diindol-12b-yl)propan-1-ol

(11d): According to the general procedure C, the treatment of indoxyl **10d** (122 mg, 0.22 mmol), with hydrazine monohydrate (110 mg, 2.21 mmol) followed by Ti(O*i*-Pr)₄ (125 mg, 2ml, 0.44 mmol) gave **11d** (36 mg, 47%) as a yellow liquid; *R*_f = 0.2 (10%/0.2% MeOH/Et₃N/CH₂Cl₂); IR (CHCl₃) *v*: 3356, 2829, 1721, 1648, 1478, 1423, 1397, 1290, 1252, 1110, 1079, 868, 728 cm⁻¹; **¹H NMR(500MHz, CD₃OD):** δ 1.55–1.63 (m, 2H), 2.29 (s, 3H), 2.25–2.31 (m, 1H), 2.52–2.59 (m, 1H), 3.09 (td, *J* = 13.4, 3.7 Hz, 1H), 3.15 (dt, *J* = 16.8, 3.1 Hz, 1H), 3.51 (t, *J* = 6.4 Hz, 2H), 4.00 (dt, *J* = 12.2, 3.3 Hz, 1H), 4.42 (td, *J* = 12.5, 2.7, 1.8 Hz, 1H), 6.58 (d, *J* = 7.9 Hz, 1H), 6.62 (s, 1H), 7.00 (td, *J* = 7.9, 0.6 Hz, 1H), 7.10 (td, *J* = 7.9, 0.9 Hz, 1H), 7.32 (d, *J* = 8.2 Hz, 1H), 7.42 (d, *J* = 7.9 Hz, 1H), 7.48 (d, *J* = 8.2 Hz, 1H); **¹³C NMR [125MHz, CD₃OD:CDCl₃(3:1)]:** 22.5 (q), 24.4 (t), 28.1 (t), 37.8 (t), 47.3 (t), 62.2 (t), 69.4 (s), 110.1 (s), 111.6 (d), 112.3 (d), 118.6 (d), 119.8 (d), 120.7 (s), 121.6 (d), 122.8 (d), 123.9 (d), 129.3 (s), 131.7 (s), 136.4 (s), 147.6 (s), 158.3 (s), 177.5 (s) ppm. ESI-MS (*m/z*): 346.11 (100%, [M+H]⁺), HRMS (ESI+): calcd. for C₂₂H₂₄N₃O, [M+H]⁺: 346.1914, found 346.1914.



3-(2-(3-(2-(1,3-Dioxoisooindolin-2-yl)ethyl)-1H-indol-2-yl)-1-hydroxy-6-methoxy-3-oxoindolin-2-yl)propyl acetate (10e):


The addition of tryptamine **4** (251 mg, 0.86 mmol) to isatogen **7e** (200 mg, 0.72 mmol), was carried out following the general procedure A to obtain N-OH indoxyl derivative **10e** (305 mg, 74%)



as a pale yellow solid M.P=193–195 °C; R_f = 0.2 (30% ethyl acetate/pet. ether); IR (CHCl₃) ν : 3368, 2929, 1707, 1605, 1494, 1452, 1397, 1290, 1289, 1102, 1024, 745, 718 cm⁻¹; **¹H NMR** (CDCl₃, 200 MHz): δ 1.47–1.75 (m, 2H), 1.99 (s, 3H), 2.39 (t, J = 5.9 Hz, 2H), 3.28 (t, J = 8.7 Hz, 2H), 3.96 (s, 3H), 3.86–3.99 (m, 4H), 6.65 (d, J = 8.5 Hz, 1H), 6.9 (s, 1H), 7.11 (app td, J = 7.0, 6.8 Hz, 1H), 7.18 (app td, J = 6.8, 6.4 Hz, 1H), 7.36 (d, J = 7.4 Hz, 1H), 7.59 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.75 (dd, J = 5.2, 3.0 Hz, 2H), 7.90 (dd, J = 5.5, 3.0 Hz, 2H), 9.08 (s, 1H), 9.48 (s, 1H); **¹³C NMR** (CDCl₃, 50 MHz): 20.8 (q), 23.6 (t), 24.0 (t), 34.8 (t), 38.9 (t), 55.8 (q), 64.0 (t), 96.0 (s), 97.0 (d), 108.2 (s), 111.1 (d), 112.7 (d), 114.4 (s), 117.9 (d), 119.5 (d), 122.8 (d), 123.5 (d, 2C), 125.3 (s), 128.2 (s), 131.9 (s, 2C), 132.6 (s), 134.2 (d, 2C), 135.1 (s), 166.5 (s), 168.3 (s), 169.1 (s, 2C), 170.9 (s), 197.5 (s) ppm. ESI-MS (*m/z*): 590.16 (100%, [M+Na]⁺), 606.12 (5%, [M+K]⁺), HRMS (ESI+): calcd. for C₃₂H₃₀O₇N₃, [M+H]⁺: 568.2078, found 568.2078.

3-(2-Methoxy-6,7,12,13-tetrahydro-12bH-azepino[3,2-b:4,5-b']diindol-12b-yl)propan-1-ol (11e):


According to the general procedure C, the treatment of indoxylo **10e** (210 mg, 0.37 mmol), with hydrazine monohydrate (185 mg, 3.70 mmol) followed by Ti(O*i*-Pr)₄ (210 mg, 0.74 mmol) gave **11e** (52 mg, 39%) as a yellow liquid; R_f = 0.2 (10%/0.2% MeOH/Et₃N/CH₂Cl₂); IR (CHCl₃) ν : 3272, 2925, 2854, 1734, 1621, 1457, 1338, 1289, 1166, 1121, 825, 744 cm⁻¹; **¹H NMR** [500MHz, CD₃OD : CDCl₃ (3:1)]: δ 1.55–1.63 (m, 2H), 2.25–2.31 (m, 1H), 2.48–2.54 (m, 1H), 3.03 (td, J = 16.8, 3.1 Hz, 1H), 3.14 (app dt, J = 16.5 Hz, 1H), 3.51 (t, J = 6.1 Hz, 2H), 3.79(s, 3H), 3.96 (d, J = 12.5 Hz, 1H), 4.37 (t, J = 12.8 Hz, 1H), 6.27 (bs, 1H), 6.31 (dd, J = 8.8, 1.8 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 7.10 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 8.8 Hz, 1H), 8.56 (bs, 1H); **¹³C NMR**



[**125MHz, CD₃OD:CDCl₃, (3:1)**]: 24.4 (t), 27.8 (t), 37.6 (t), 47.0 (t), 55.9 (q), 62.1 (t), 69.4 (s), 94.9 (d), 108.6 (d), 109.9 (s), 111.4 (d), 116.0 (s), 118.4 (d), 119.6 (d), 122.5 (d), 125.2 (d), 129.0 (s), 131.6 (s), 136.1 (s), 159.5 (s), 166.9 (s), 175.9 (s) ppm. ESI-MS (*m/z*): 362.15 (100%, [M+H]⁺), HRMS (ESI+): calcd. for C₂₂H₂₄N₃O₂, [M+H]⁺: 362.1863, found 362.1865.

2-(2-(2-(3-(Benzylxy)propyl)-1-hydroxy-6-methyl-3-oxoindolin-2-yl)-1H-indol-3-yl)ethylisoindoline-1,3-dione (10f):


The addition of tryptamine **4** (123 mg, 0.43 mmol) to isatogen **7f** (110 mg, 0.35 mmol), was carried out following the general procedure A to obtain indoxyl derivative **10f** (127 mg, 60%) as a brown red liquid; *R_f* = 0.4 (20% ethyl acetate/pet. ether); IR (CHCl₃) *v*: 3243, 3051, 2863, 1728, 1654, 1369, 1243, 1021, 823, 754 cm⁻¹; **1H NMR (CDCl₃, 500 MHz)**:



δ 1.51–1.56 (m, 1H), 1.64–1.71 (m, 1H), 2.41 (t, *J* = 8.3 Hz, 2H), 2.47 (s, 3H), 3.22–3.28 (m, 2H), 3.36–3.42 (m, 2H), 3.83–3.91 (m, 1H), 4.0–4.06 (m, 1H), 4.42 (s, 2H), 6.90 (d, *J* = 8.0 Hz, 1H), 7.07 (dt, *J* = 7.8 Hz, 1H), 7.13 (dt, *J* = 8.0, 1.0 Hz, 1H), 7.25–7.30 (m, 7H), 7.56 (d, *J* = 8.0 Hz, 1H), 7.62 (d, *J* = 7.9 Hz, 1H), 7.74 (dd, *J* = 5.5, 3.0 Hz, 1H), 7.89 (dd, *J* = 5.2, 3.0 Hz, 2H), 8.97 (bs, 1H), 9.48 (bs, 1H); **¹³C NMR (CDCl₃, 100 MHz)**: 22.6 (q), 23.6 (t), 25.0 (t), 34.7 (t), 38.9 (t), 69.9 (t), 72.8 (t), 76.5 (s), 108.4 (s), 111.1 (d), 114.9 (d), 117.9 (d), 119.1 (d), 119.5 (s), 122.0 (d), 123.5 (d), 123.5 (d), 124.5 (d), 127.5 (d), 127.7 (d), 128.3 (d), 128.3 (s), 131.9 (s), 132.7 (s), 134.3 (d), 135.1 (s), 138.3 (s), 149.8 (s), 164.2 (s), 169.2 (s), 199.5(s), ppm; ESI-MS (*m/z*): 560.17 (100%, [M+Na]⁺), HRMS (ESI+): calcd. for C₃₇H₃₃O₅N₃, [M+Na]⁺: 622.2312, found 538.2308.


12b-(3-(Benzylxy)propyl)-2-methyl-7,12,12b,13-tetrahydro-6H-azepino[3,2-b:4,5-b']diindole (11f):

According to the general procedure C, the treatment of indoxyl **10f** (52 mg, 0.09 mmol) with hydrazine monohydrate (43 mg, 0.9 mmol) followed by Ti(O*i*-Pr)₄ (49 mg, 0.17 mmol) gave the **11a** (19 mg, 52%) as a yellow liquid; *R_f* = 0.4 (80% ethyl acetate/pet. ether); IR (CHCl₃)




ν : 3063, 2832, 1654, 1552, 1321, 1289, 1093, 1045, 864, 735 cm^{-1} ; **$^1\text{H NMR}$ (500MHz, CDCl_3):** δ 1.67–1.84 (m, 2H), 1.28 (s, 3H), 2.40–2.49 (m, 2H), 3.04–3.11 (m, 2H), 3.50 (t, J = 5.9 Hz, 2H), 4.18 (app td, J = 11.7, 3.6 Hz, 1H), 4.37 (dt, J = 11.5, 5.3 Hz, 1H), 4.52 (s, 2H), 6.46 (bs, 1H), 6.65 (dd, J = 7.8, 0.6 Hz, 1H), 7.06 (dt, J = 7.3, 1.3 Hz, 1H), 7.14 (dt, J = 7.6, 1.3 Hz, 1H), 7.22 (bs, 1H), 7.36 (bs, 5H), 7.44 (bs, 1H), 7.50 (d, J = 8.1 Hz, 1H), 8.36 (bs, 1H); **$^{13}\text{C NMR}$ (125MHz, CDCl_3):** 22.1 (q), 23.6 (t), 24.8 (t), 29.3 (t), 31.9 (t), 37.2 (t), 69.7 (t), 71.3 (s), 73.3 (t), 105.1 (s), 109.4 (s), 109.7 (s), 110.3 (s), 110.9 (d), 111.8 (d), 117.8 (d), 119.4 (d), 121.7 (d), 122.4 (d), 127.8 (2C, d), 127.9 (d), 128.3 (d), 128.5 (2C, d), 135.1 (s), 137.7 (s), 140.9 (s), 161.6 (s), 172.7 (s) ppm. ESI-MS (m/z): 436.21 (100%, $[\text{M}+\text{H}]^+$), HRMS (ESI+): calcd. for $\text{C}_{24}\text{H}_{28}\text{N}_3\text{O}_2$, $[\text{M}+\text{H}]^+$: 436.2383, found 436.2384.

Synthesis of Compound (11g): Compound **11g** (45 mg, 27%) was prepared by the addition of tryptamine **4** (175 mg, 0.61 mmol) to isatogen **7g** (120 mg, 0.51 mmol) followed by subjecting the resulting crude indoxyl derivative **10g** with hydrazine monohydrate (134 mg, 2.7 mmol) and then with $\text{Ti}(\text{O}i\text{-Pr})_4$ (152 mg, 0.54 mmol). Pale yellow solid; R_f = 0.4 (10%/0.2% MeOH/Et₃N/CH₂Cl₂); M.P=153–155 °C; IR (CHCl₃) ν : 3273, 2925, 2851, 1658, 1610, 1458, 1320, 1290, 1289, 1151, 1024, 744, 718 cm^{-1} ; **$^1\text{H NMR}$ (CDCl₃, 400 MHz):** δ 2.13–2.18 (m, 1H), 2.23–2.32 (m, 2H), 2.35 (s, 3H), 2.62–2.66 (m, 1H), 3.0–3.08 (m, 1H), 3.1–3.16 (dt, J = 16.9, 3.4 Hz, 1H), 3.28 (dt, J = 9.3, 9.1 Hz, 1H), 3.85–3.9 (m, 1H), 4.22–4.26 (m, 2H), 6.68 (s, 1H), 6.76 (d, J = 7.8 Hz, 1H), 7.07 (app td, J = 7.1, 7.8 Hz, 1H), 7.14 (td, J = 7.1, 7.8 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 8.13 (s, 1H); **$^{13}\text{C NMR}$ (CDCl₃, 100 MHz):** 22.1 (q), 23.0 (t), 28.0 (t), 37.1 (t), 48.5 (t), 53.6 (t), 74.6 (s), 109.5 (s), 110.7 (d), 112.4 (s), 114.3 (d), 118.1 (d), 119.5 (d), 122.0 (d), 122.6 (d), 123.0 (d), 129.5 (s), 133.4 (s), 134.9 (s), 144.4 (s), 159.8 (s), 175.1 (s) ppm. ESI-MS (m/z): 328.16 (100%, $[\text{M}+\text{H}]^+$), HRMS (ESI+): calcd. for $\text{C}_{22}\text{H}_{22}\text{N}_3$ $[\text{M}+\text{H}]^+$: 328.1808, found 328.1808.




N-Phthalimido 4-(4-methoxy-2-nitrophenyl)but-3-yn-1-amine (12):

To a solution of the alkyne **6** (1.8 g, 9.05 mmol) and an aryl iodide **5**



(3.028 g, 10.85 mmol) in THF (8 mL) and Et₃N (8 mL), were added triphenylphosphine (475 mg, 1.81 mmol) and Pd(PPh₃)₂Cl₂ (315 mg, 0.45 mmol) and the mixture was degassed with argon for 10 min. To this CuI (345 mg, 1.81 mmol) was introduced and the mixture was degassed with argon for 10 min and stirred at room temperature for 6 h under argon atmosphere. After completion of the reaction as indicated by TLC, the volatiles are removed under reduced pressure and residue was purified by column chromatography to yield **12** (2.6 g, 82%) as pale yellow solid. R_f = 0.10 (20% ethyl acetate/pet ether); M.P = 118–120 °C; IR (CHCl₃) ν : 3399, 3225, 2952, 1701, 1628, 1316, 1215, 1108, 821, 745 cm⁻¹; **1H NMR** (CDCl₃, 200 MHz): δ 2.87 (t, J = 7.0 Hz, 2H), 3.84 (s, 3H), 3.96 (t, J = 7.1 Hz, 2H), 7.05 (dd, J = 8.7, 2.6 Hz, 1H), 7.43 (d, J = 2.6 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.71 (dd, J = 5.6, 3.0 Hz, 2H), 7.85 (dd, J = 5.7, 3.1 Hz, 2H); **13C NMR** (CDCl₃, 50 MHz): 19.8 (t), 36.5 (t), 55.9 (q), 77.5 (s), 92.3 (s), 109.0 (d), 110.8 (s), 119.7 (d), 123.4 (d), 132.0 (s), 134.1 (d), 135.8 (d), 150.7 (s), 159.1 (s), 168.2 (s) ppm. ESI-MS (*m/z*): 372.92 (100%, [M+Na]⁺), HRMS (ESI+): calcd. for C₁₉H₁₄N₂O₅, [M+Na]⁺: 373.0795, found 373.0792.


Synthesis of isatogen 3: PdCl₂ (13 mg, 0.073 mmol, 5 mol%) was added to a solution of an alkyne **12** (300 mg, 1.5 mmol) in CH₃CN (30 mL), and the mixture was stirred under argon at room temp. for 11 h.



The reaction mixture was concentrated, and the residue obtained was purified by column chromatography (ethyl acetate in petroleum ether) to afford a compound **3** (159 mg, 53% yield) as yellow solid. R_f (40% ethyl acetate/pet. ether) 0.50 ; IR (CHCl₃) ν : 3399, 3225, 2952, 1701, 1628, 1316, 1215, 1108, 821, 745 cm⁻¹; **1H NMR** (CDCl₃, 200 MHz): δ 2.87 (t, J = 6.1 Hz, 2H),


3.90 (s, 3H), 4.02 (t, J = 6.1 Hz, 2H), 6.90 (dd, J = 8.2, 2.1 Hz, 1H), 7.12 (d, J = 2.1 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.69 (dd, J = 5.4, 3.1 Hz, 2H), 7.78 (dd, J = 5.7, 3.0 Hz, 2H); **^{13}C NMR** (CDCl_3 , 125 MHz): 21.3 (t), 34.1 (t), 56.3 (q), 101.5 (d), 114.9 (d), 115.3 (d), 123.3 (d, 2C), 123.4 (d), 132.0 (s, 2C), 133.9 (d, 2C), 137.1 (s), 150.1 (s), 165.3 (s), 168.2 (s, 2C), 185.3 (s) ppm. ESI-MS (m/z): 373.07 (100%, $[\text{M}+\text{Na}]^+$), 389.08 (5%, $[\text{M}+\text{K}]^+$), HRMS (ESI+): calcd. for $\text{C}_{19}\text{H}_{14}\text{N}_2\text{O}_5$, $[\text{M}+\text{Na}]^+$: 373.0795, found 373.0791.

Preparation of indoxyl (2): The addition of tryptamine **4** (140 mg, 0.48 mmol) to isatogen **3** (140 mg, 0.40 mmol) was carried out following the general procedure A to obtain indoxyl **2** as yellow solid (182 mg, 71%); R_f = 0.3 (40% ethyl acetate/pet. ether); M.P = 227–




228 °C; IR (CHCl_3) ν : 3389, 3235, 2963, 1701, 1628, 1361, 1223, 1118, 825, 725 cm^{-1} ; **^1H NMR** (CDCl_3 , 400 MHz): δ 2.61–2.68 (m, 1H), 2.70–2.78 (m, 1H), 3.11 (m, 1H), 3.22–3.25 (m, 1H), 3.84–3.88 (m, 3H), 3.96 (s, 3H), 4.07 (m, 1H), 6.65 (d, J = 8.3 Hz, 1H), 6.92 (s, 1H), 6.99 (app td, J = 7.3 Hz, 1H), 7.08 (app td, J = 7.3 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.53 (d, J = 9.0 Hz, 1H), 7.56 (d, J = 9.3 Hz, 1H), 7.63 (dd, J = 5.1, 3.0 Hz, 2H), 7.72 (dd, J = 5.1, 3.0 Hz, 2H), 7.74 (dd, J = 5.1, 3.1 Hz, 2H), 7.84 (dd, J = 5.1, 3.4 Hz, 2H), 9.01 (s, 1H), 9.69 (s, 1H); **^{13}C NMR** (CDCl_3 , 100 MHz): 23.6 (t), 34.4 (t), 34.7 (t), 38.7 (t), 55.9 (q), 75.4 (s), 97.2 (d), 109.1 (s), 111.2 (d), 112.8 (d), 113.8 (s), 117.9 (d), 119.5 (d), 122.1 (d), 123.1 (d, 2C), 123.4 (d, 2C), 125.7 (d), 128.4 (s), 131.0 (s), 131.9 (s, 4C), 133.8 (d, 2C), 134.2 (d, 2C), 135.4 (s), 165.4 (s), 168.0 (s, 2C), 168.3 (s), 169.2 (s, 2C), 195.9 (s) ppm. ESI-MS (m/z): 663.23 (100%, $[\text{M}+\text{Na}]^+$), 679.19 (50%, $[\text{M}+\text{K}]^+$), HRMS (ESI+): calcd. for $\text{C}_{37}\text{H}_{29}\text{N}_4\text{O}_7$, $[\text{M}+\text{H}]^+$: 641.2031, found 641.2030.

Synthesis of (\pm)-Trigonoliimine C (1): The general procedure B has been followed for the phthalimide deprotection/N–O reduction of indoxyl **2** (100 mg, 0.15 mmol) with hydrazine monohydrate (78 mg, 1.56 mmol) and then procedure D was followed for the cyclization of resulting amine using $Ti(O^iPr)_4$ (88 mg, 0.31 mmol) followed by usual workup and purification column chromatography (neutral silica gel, 10% MeOH and 0.2% NH_4OH in CH_2Cl_2 as eluent) gave the cyclized compound (20 mg) which was subjected for *N*-formylation^{1,2} immediately using freshly prepared *N*-formyl benzotriazole (8.5 mg, 0.06 mmol, 1eq) and THF (1ml) as a solvent to provide (\pm)-Trigonoliimine C (18 mg, 31% yield over 3 steps); IR ($CHCl_3$) ν : 3272, 2925, 2854, 1734, 1621, 1457, 1338, 1289, 1166, 1121, 825, 744 cm⁻¹; **¹H NMR** [(500MHz, CD₃OD:CDCl₃ (3:1))]: δ 2.45–2.5 (m, 1H), 2.61–2.67 (m, 1H), 3.03 (td, J = 16.8, 13.4, 3.4 Hz, 1H), 3.12 (app dt, J = 16.9 Hz, 1H), 3.20–3.29 (m, 2H), 3.79 (s, 3H), 3.98 (app dt, J = 12.7, 3.4 Hz, 1H), 4.33 (app td, J = 12.7, 2.4 Hz, 1H), 6.29 (d, J = 2.0 Hz, 1H), 6.31 (dd, J = 8.6, 1.5 Hz, 1H), 7.02 (t, J = 7.1 Hz, 1H), 7.12 (app td, J = 7.1 Hz, 1H), 7.32 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.49 (d, J = 8.8 Hz, 1H), 7.92 (s, 1H); **¹³C NMR** [(100MHz, CD₃OD:CDCl₃ (3:1))]: δ 24.7 (t), 35.0 (t), 40.4 (t), 47.2 (t), 56.2 (q), 68.9 (s), 95.3 (d), 109.6 (s), 110.5 (d), 111.8 (d), 115.6 (d), 118.8 (d), 120.0 (d), 123.1 (d), 125.7 (s), 129.5 (s), 131.0 (s), 136.7 (s), 160.4 (s), 163.8 (d), 168.0 (s), 173.2 (s), ppm; ESI-MS (*m/z*): 375.02 (100%, [M+H]⁺), HRMS (ESI+): calcd. for C₂₂H₂₃N₄O₂, [M+H]⁺: 375.1816, found 375.1814.




1. R. Katritzky, H. X. Chang and B. Z. Yang, *Synthesis*, 1995, 503–505.
2. S. Han and M. Movassaghi, *J. Am. Chem. Soc.*, 2011, **133**, 10768–10771.


Comparison of ^{13}C NMR Spectra for Synthetic Trigonoliimine C and Natural Trigonoliimine C





Carbon	δ_{C} Synthesized CD ₃ OD:CDCl ₃ (3:1)	δ_{C} reported by UK Tambar ³ CD ₃ OD:CDCl ₃	δ_{C} reported by Hao ⁴ CD ₃ OD:CDCl ₃
1 (NH)	-	-	-
2	131.03	131.7	131.4
3	110.49	110.5	110.3
4	118.77	118.8	118.5
5	120.05	119.96	119.7
6	123.07	122.93	122.7
7	111.83	111.73	111.5
8	136.72	136.85	136.3
9	129.51	129.69	129.2
10	24.68	24.59	24.3
11	47.19	47.68	47.5
13(NH)	-	-	-
14	68.87	68.62	68.1
15	173.2	175.57	174.9
16	115.61	116.62	116.5
17	125.75	125.5	125.2
18	109.65	108.93	108.4
19	167.98	167.45	166.8
20	95.28	95.57	95.3
21	160.40	159.73	159.0
22	40.38	40.53	40.2
23	35.03	35.08	34.9
24(NH)	-	-	-
25	163.76	163.78	163.4
OMe	56.17	55.98	55.8

- 3) X. B. Qi, H. L. Bao, and U. K. Tambar, *J. Am. Chem. Soc.*, 2011, **133**, 10050
- 4) C. J. Tan, Y. T. Di, Y. H. Wang, Y. Zhang, Y. K. Si, Q. Zhang, S. Gao, X. J. Hu, X. Fang, S. F. Li and X. J. Hao, *Org. Lett.*, 2010, **12**, 2370.










F:\DATA\JAN-2013\15\NPR-12

1/15/2013 4:01:53 PM

NPR-12 #7-22 RT: 0.11-0.37 AV: 16 SB: 30 0.00-0.16 , 0.35-0.68 NL: 8.02E4
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]




779.42

401.08

433.15

8a


Relative Abundance
ESI 23




D:\Data\NPR12

1/18/2013 6:07:43 PM


NPR12 #1043 RT: 4.65 AV: 1 NL: 4.78E8
T: FTMS + p ESI Full ms [100.00-700.00]





8a




28 Jan 2013



Acquisition Time (sec)	2.7329	Comment	Narendra	Date	19/01/2013 09:00:30
Frequency (MHz)	50.32	Nucleus	13C	Original Points Count	32768
Temperature (grad C)	0.000	Points Count	32768	Sweep Width (Hz)	11990.41






F:\DATA\JAN-2013\17\NPR-NOH

NPR-NOH #7-29 RT: 0.10-0.49 AV: 23 SB: 35 0.00-0.21, 0.40-0.76 NL: 1.41E6
T: {0,0} + c ESI corona sid=80.00 det=1400.00 Full ms [100.00-2000.00]
385.01





9



D:\Data\NPR-21

1/24/2013 3:30:57 PM



NPR-21 #1079 RT: 4.81 AV: 1 NL: 1.35E9
T: FTMS + p ESI Full ms [100.00-700.00]





9


9

12 Aug 2013



12 Aug 2013







F:\DATA\JAN-2013\15\NPR-03

1/15/2013 3:42:12 PM

NPR-03 #7-30 RT: 0.11-0.51 AV: 24 SB: 24 0.00-0.11, 0.42-0.70 NL: 3.35E5
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]

544.25



D:\Data\NPR3


1/18/2013 7:03:50 PM

NPR3 #1116 RT: 4.97 AV: 1 NL: 6.10E8
T: FTMS + p ESI Full ms [100.00-700.00]


538.2336
R=48307
 $C_{32}H_{32}O_5N_3 = 538.2336$
-0.1227 ppm




12 Aug 2013



12 Aug 2013






F:\DATA\JAN-2013\15\NPR-17

1/15/2013 4:13:11 PM


NPR-17 #7-20 RT: 0.11-0.33 AV: 14 SB: 18 0.00-0.14 , 0.30-0.44 NL: 2.87E5
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
374.15



D:\Data\NPR17


1/18/2013 3:07:08 PM

NPR17 #5118 RT: 2.31 AV: 1 NL: 4.34E9
T: FTMS + p ESI Full ms [100.00-700.00]



11a


374.22225
R=58307
C₂₄H₂₈O N₃ = 374.2227
-0.5769 ppm




360.2071
R=52602
C₂₃H₂₆O N₃ = 360.2070
0.1480 ppm


383.9316
R=31600
390.2167
R=56707
390
395
400
385
380
375
370
365
360
355
350
m/z

27 Dec 2012







27 Dec 2012



F:\DATA\JAN-2013\15\NPR-05

1/15/2013 3:46:53 PM


NPR-05 #6-21 RT: 0.09-0.35 Av: 16 SB: 21 0.02-0.11 0.37-0.61 NL: 9.04E5
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
530.24




D:\Data\NPR5

1/18/2013 7:26:12 PM


NPR5 #1158 RT: 5.16 AV: 1 NL: 3.33E8
T: FTMS + p ESI Full ms [100.00-700.00]




27 Dec 2012




Acquisition Time (sec)	3.9846	Comment	1H	Date	22/07/2012 16:30:24
Nucleus	1H	Original Points Count	32768	Points Count	32768
Temperature (grad C)	0.000	Sweep Width (Hz)	8223.68		5






27 Dec 2012




F:\DATA\JAN-2013\15\NPR-15

1/15/2013 4:07:54 PM

NPR-15 #8-19 RT: 0.12-0.32 AV: 12 SB: 19 0.02-0.14 , 0.30-0.47 NL: 1.55E5
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
358.15




11b





D:\Data\NPR15_130118144308

1/18/2013 2:43:08 PM


NPR15_130118144308 #526 RT: 2.34 AV: 1 NL: 2.83E9
T: FTMS⁻ + p ESI Full ms [100.00-700.00]




11b




27 Dec 2012





27 Dec 2012




F:\DATA\JAN-2013\15NPR-1_130115153430


1/15/2013 3:34:30 PM

NPR-1_130115153430 #7-22 RT: 0.10-0.36 AV: 16 SB: 24 0.02-0.14, 0.42-0.68 NL: 9.50E5
T: {0.0} + c ESI corona sid=80.00 det=1400.00 Full ms [100.00-2000.00]

560.17



10c



D:\Data\NPR1

1/18/2013 6:41:27 PM

NPR1 #984 RT: 4.38 AV: 1 NL: 3.88E8
T: FTMS + p ESI Full ms [100.00-700.00]

560.1791
R=47607
 $C_{31}H_{27}O_6N_3Na = 560.1792$


-0.1223 ppm

538.1973

R=48307

$C_{31}H_{28}O_6N_3 = 538.1973$

0.0067 ppm



10c

100

90

80

70

60

50

40

30

20

10

0

Relative Abundance

ESI 54

576.1530
R=46707

520.1870
R=48307
 $C_{31}H_{26}O_5N_3 = 520.1867$

0.4869 ppm

549.1821
R=46407

566.6599
R=42402

583.2549
R=45107

597.2707
R=45207

600

590

580

570

560

550

540

530

520

510

500

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530

520

510

590

580

570

560

550

540

530


520

510

590

580</


1HWed3av500#004.esp




11c



1HWed3av500#004.esp

1HWed3av500#004.esp






Wed3av500#004.Dept.esp



F:\DATA\JAN-2013\15\NPR-13

1/15/2013 4:03:55 PM


NPR-13 #8-18 RT: 0.12-0.30 AV: 11 SB: 17 0.00-0.12, 0.28-0.42 NL: 4.50E5
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
332.10




D:\Data\NPR13


1/18/2013 6:18:58 PM

NPR13 #507 RT: 2.26 AV: 1 NL: 3.37E9
T: FTMS + p ESI Full ms [100.00-700.00]






11c






26 Jun 2013
AC38 Wed2av500#02
narendra







D:\Data\NPR-1

NPR-1 #1002 RT: 4.47 AV: 1 NL: 4.16E8
T: FTMS + p ESI Full ms [100.00-700.00]


6/25/2013 3:03:07 PM


574.1943
R=46907
 $C_{32}H_{29}O_6N_3Na = 574.1949$
-0.9071 ppm


100


95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0

Relative Abundance










F:\DATA\JAN-2013\15\NPR-18

1/15/2013 4:16:35 PM

NPR-18 #7-20 RT: 0.11-0.33 AV: 14 SB: 24 0.00-0.14, 0.39-0.63 NL: 2.03E6
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
346.11





11d




D:\Data\NPR18

1/18/2013 3:18:23 PM


NPR18 #520 RT: 2.31 AV: 1 NL: 1.57E10
T: FTMS + p ESI Full ms [100.00-700.00]




27 Dec 2012




Acquisition Time (sec)	7.9167	Comment	narendra	Date	18/12/2012 20:45:06
Frequency (MHz)	200.13	Nucleus	1H	Original Points Count	32768
Temperature (grad C)	0.000			Points Count	32768






27 Dec 2012



F:\DATAJAN-2013\15\NPR-04

1/15/2013 3:44:56 PM


NPR-04 #7-25 RT: 0.11-0.42 AV: 19 SB: 26 0.00-0.11 , 0.44-0.76 NL: 1.75E6
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
590.16





D:\Data\NPR4


1/18/2013 7:15:02 PM

NPR4 #961 RT: 4.28 AV: 1 NL: 5.89E8
T: FTMS + p ESI Full ms [100.00-700.00]











11e




F:\DATA\JAN-2013\15\NPR-14

1/15/2013 4:05:55 PM

NPR-14 #7-20 RT: 0.11-0.33 AV: 14 SB: 25 0.00-0.11, 0.37-0.67 NL: 7.47E4
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
362.15



11e




D:\Data\NPR14


1/18/2013 6:30:10 PM


NPR14 #5112 RT: 2.28 AV: 1 NL: 1.08E9
T: FTMS + p ESI Full ms [100.00-700.00]


362.1865
R=59007
 $C_{22}H_{24}O_2N_3 = 362.1863$
0.6072 ppm




11e










F:\DATA\VAug-2013\13\NPR-1


8/13/2013 1:19:34 PM

NPR-1 #8-25 RT: 0.12-0.42 AV: 18 SB: 17 0.02-0.10 , 0.35-0.52 NL: 1.28E6
T: {0,0} + c ESI corona sid=75.00 det=1600.00 Full ms [100.00-2000.00]

100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0




Relative Abundance






D:\Data\NPR-MEOBN

NPR-MEOBN #1078 RT: 4.80 AV: 1 NL: 6.12E8
T: FTMS + p ESI Full ms [100.00-700.00]


8/13/2013 6:54:01 PM








Fri3av500#013.002511r.esp



11f



F:\DATA\JAN-2013\15\NPR-19

1/15/2013 4:18:18 PM



NPR-19 #8-17 RT: 0.12-0.28 AV: 10 SB: 23 0.00-0.12, 0.37-0.61 NL: 3.37E5
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
436.21




D:\Data\NPR19


1/18/2013 3:29:33 PM


NPR19 #529 RT: 2.35 AV: 1 NL: 5.30E9
T: FTMS + pESI Full ms [100.00-700.00]




11f










F:\DATA\JAN-2013\15INPR-16_130115161447

1/15/2013 4:14:47 PM

NPR-16_130115161447 #7-20 RT: 0.11-0.33 AV: 14 SB: 22 0.00-0.14 , 0.40-0.61 NL: 5.51E5
T: {0,0} + c ESI corona sid=40.00 det=1400.00 Full ms [100.00-1500.00]
328.16




D:\Data\NPR16

1/18/2013 2:55:55 PM

NPR16 #5116 RT: 2.30 AV: 1 NL: 1.17E10
T: FTMS + p ESI Full ms [100.00-700.00]


328.1808
R=62503
 $C_{22}H_{22}N_3 = 328.1808$
-0.2092 ppm




11g

ESI 94


Relative Abundance





31 Dec 2012




12










D:\Data\NPR-2


NPR-2 #1006 RT: 4.48 AV: 1 NL: 5.17E8
T: FTMS + p ESI Full ms [100.00-700.00]


373.0792 R=58107
C₁₉H₁₄O₅N₂ Na = 373.0795
-0.8849 ppm




12












D:\Data\NPR-4


NPR-4 #911 RT: 4.06 AV: 1 NL: 5.04E8
T: FTMS + p ESI Full ms [100.00-700.00]


6/25/2013 3:36:40 PM












D:\Data\NPR10


1/18/2013 4:03:11 PM


NPR10 #985 RT: 4.39 AV: 1 NL: 3.42E8
T: FTMS + p ESI Full ms [100.00-700.00]




2

663.1846
R=43607
 $C_{37}H_{28}O_7N_4 Na = 663.1850$
-0.6786 ppm







Thu5av500#013.001.001.1r.esp



Thu5av500#013.001.001.1r.esp






F:\DATA\MARCH-2013\14\NPR-C

3/14/2013 4:10:08 PM

NPR-C #8-49 RT: 0.12-0.84 AV: 42 SB: 41 0.00-0.25 0.56-1.00 NL: 4.04E5
T: {0,0} + c ESI corona sid=40.00 det=1600.00 Full ms [100.00-1500.00]
389.02




D:\Data\NPR20

1/18/2013 3:40:47 PM

NPR20 #516 RT: 2.30 AV: 1 NL: 2.61E9
T: FTMS + p ESI Full ms [100.00-700.00]

375.1814
R=58307
 $C_{22}H_{23}O_2N_4 = 375.1816$
-0.3345 ppm



1

Relative Abundance 113 ESI

100
90
80
70
60
50
40
30
20
10
0

